Gaucher disease.
Identifieur interne : 002509 ( Main/Merge ); précédent : 002508; suivant : 002510Gaucher disease.
Auteurs : Pascal Guggenbuhl [France] ; Bernard Grosbois ; Gérard ChalèsSource :
- Joint, bone, spine : revue du rhumatisme [ 1778-7254 ] ; 2008.
English descriptors
- KwdEn :
- MESH :
- chemical , deficiency : Glucosylceramidase.
- complications : Gaucher Disease.
- etiology : Bone Diseases, Metabolic, Osteonecrosis.
- genetics : Gaucher Disease, Glucosylceramidase, Mutation.
- therapy : Gaucher Disease.
- Humans.
Abstract
Gaucher disease is an inherited recessive autosomal metabolic defect due to a deficiency of the lysosomal enzyme beta-glucocerebrosidase. The enzyme substrate, glucocerebroside, accumulates in the body, predominantly in the liver, spleen, and bone marrow. Osteoarticular manifestations are often inaugural and contribute much of the morbidity and disability associated with Gaucher disease. There are three types of Gaucher disease. The most common is type 1, which can produce a broad range of presentations characterized by cytopenia and involvement of the spleen, liver, and bone marrow. Types 2 and 3 are rarest variants that manifest in infancy and cause neurologic damages. Patients with type 2 Gaucher disease usually die before 2years of age. beta-glucocerebrosidase assays and examination of bone marrow smears and biopsies ensure the diagnosis. Specific mutations in the beta-glucocerebrosidase gene are associated with specific clinical presentations: thus, the N370S mutation (heterozygous or homozygous) confers type 1 disease and the L444P mutation neurologic involvement and type 3 disease. Bone involvement is a feature in 70%-100% of cases. Abnormal bone remodeling, osteonecrosis and bony infarcts, osteopenia with fractures, and more rarely infections may occur. The other manifestations are dominated by cytopenia (thrombocytopenia, neutropenia, or anemia), hypersplenism, and liver enlargement. The risk of myeloma is increased. Parkinson-like syndromes were recently described in patients with type 1 disease. The enzyme chitotriosidase can be assayed to quantify the degree of macrophage activation. The chemokine CCL18 is another valuable marker but is not readily available in everyday practice. The treatment of Gaucher disease includes symptomatic drugs to relieve pain. Splenectomy is rarely necessary now that specific treatments are available. Enzyme replacement therapy (imiglucerase) has considerably improved the management of the highest risk patients. More recently, an enzyme inhibitor that decreases the production of the substrate (miglustat) was introduced. Chemical chaperone therapy and gene therapy hold promise for the future.
DOI: 10.1016/j.jbspin.2007.06.006
PubMed: 17996473
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000D15
- to stream PubMed, to step Curation: 000C75
- to stream PubMed, to step Checkpoint: 000C75
- to stream Ncbi, to step Merge: 000784
- to stream Ncbi, to step Curation: 000784
- to stream Ncbi, to step Checkpoint: 000784
Links to Exploration step
pubmed:17996473Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Gaucher disease.</title>
<author><name sortKey="Guggenbuhl, Pascal" sort="Guggenbuhl, Pascal" uniqKey="Guggenbuhl P" first="Pascal" last="Guggenbuhl">Pascal Guggenbuhl</name>
<affiliation wicri:level="3"><nlm:affiliation>Rheumatology Department, Hôpital Sud, Rennes Teaching Hospital, Rennes, France; INSERM U522, IFR 140, Rennes1, Rennes, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Rheumatology Department, Hôpital Sud, Rennes Teaching Hospital, Rennes, France; INSERM U522, IFR 140, Rennes1, Rennes</wicri:regionArea>
<placeName><region type="region">Région Bretagne</region>
<region type="old region">Région Bretagne</region>
<settlement type="city">Rennes</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Grosbois, Bernard" sort="Grosbois, Bernard" uniqKey="Grosbois B" first="Bernard" last="Grosbois">Bernard Grosbois</name>
</author>
<author><name sortKey="Chales, Gerard" sort="Chales, Gerard" uniqKey="Chales G" first="Gérard" last="Chalès">Gérard Chalès</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2008">2008</date>
<idno type="RBID">pubmed:17996473</idno>
<idno type="pmid">17996473</idno>
<idno type="doi">10.1016/j.jbspin.2007.06.006</idno>
<idno type="wicri:Area/PubMed/Corpus">000D15</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000D15</idno>
<idno type="wicri:Area/PubMed/Curation">000C75</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000C75</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000C75</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000C75</idno>
<idno type="wicri:Area/Ncbi/Merge">000784</idno>
<idno type="wicri:Area/Ncbi/Curation">000784</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000784</idno>
<idno type="wicri:Area/Main/Merge">002509</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Gaucher disease.</title>
<author><name sortKey="Guggenbuhl, Pascal" sort="Guggenbuhl, Pascal" uniqKey="Guggenbuhl P" first="Pascal" last="Guggenbuhl">Pascal Guggenbuhl</name>
<affiliation wicri:level="3"><nlm:affiliation>Rheumatology Department, Hôpital Sud, Rennes Teaching Hospital, Rennes, France; INSERM U522, IFR 140, Rennes1, Rennes, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Rheumatology Department, Hôpital Sud, Rennes Teaching Hospital, Rennes, France; INSERM U522, IFR 140, Rennes1, Rennes</wicri:regionArea>
<placeName><region type="region">Région Bretagne</region>
<region type="old region">Région Bretagne</region>
<settlement type="city">Rennes</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Grosbois, Bernard" sort="Grosbois, Bernard" uniqKey="Grosbois B" first="Bernard" last="Grosbois">Bernard Grosbois</name>
</author>
<author><name sortKey="Chales, Gerard" sort="Chales, Gerard" uniqKey="Chales G" first="Gérard" last="Chalès">Gérard Chalès</name>
</author>
</analytic>
<series><title level="j">Joint, bone, spine : revue du rhumatisme</title>
<idno type="eISSN">1778-7254</idno>
<imprint><date when="2008" type="published">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Bone Diseases, Metabolic (etiology)</term>
<term>Gaucher Disease (complications)</term>
<term>Gaucher Disease (genetics)</term>
<term>Gaucher Disease (therapy)</term>
<term>Glucosylceramidase (deficiency)</term>
<term>Glucosylceramidase (genetics)</term>
<term>Humans</term>
<term>Mutation (genetics)</term>
<term>Osteonecrosis (etiology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="deficiency" xml:lang="en"><term>Glucosylceramidase</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Gaucher Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Bone Diseases, Metabolic</term>
<term>Osteonecrosis</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Gaucher Disease</term>
<term>Glucosylceramidase</term>
<term>Mutation</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Gaucher Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Gaucher disease is an inherited recessive autosomal metabolic defect due to a deficiency of the lysosomal enzyme beta-glucocerebrosidase. The enzyme substrate, glucocerebroside, accumulates in the body, predominantly in the liver, spleen, and bone marrow. Osteoarticular manifestations are often inaugural and contribute much of the morbidity and disability associated with Gaucher disease. There are three types of Gaucher disease. The most common is type 1, which can produce a broad range of presentations characterized by cytopenia and involvement of the spleen, liver, and bone marrow. Types 2 and 3 are rarest variants that manifest in infancy and cause neurologic damages. Patients with type 2 Gaucher disease usually die before 2years of age. beta-glucocerebrosidase assays and examination of bone marrow smears and biopsies ensure the diagnosis. Specific mutations in the beta-glucocerebrosidase gene are associated with specific clinical presentations: thus, the N370S mutation (heterozygous or homozygous) confers type 1 disease and the L444P mutation neurologic involvement and type 3 disease. Bone involvement is a feature in 70%-100% of cases. Abnormal bone remodeling, osteonecrosis and bony infarcts, osteopenia with fractures, and more rarely infections may occur. The other manifestations are dominated by cytopenia (thrombocytopenia, neutropenia, or anemia), hypersplenism, and liver enlargement. The risk of myeloma is increased. Parkinson-like syndromes were recently described in patients with type 1 disease. The enzyme chitotriosidase can be assayed to quantify the degree of macrophage activation. The chemokine CCL18 is another valuable marker but is not readily available in everyday practice. The treatment of Gaucher disease includes symptomatic drugs to relieve pain. Splenectomy is rarely necessary now that specific treatments are available. Enzyme replacement therapy (imiglucerase) has considerably improved the management of the highest risk patients. More recently, an enzyme inhibitor that decreases the production of the substrate (miglustat) was introduced. Chemical chaperone therapy and gene therapy hold promise for the future.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002509 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 002509 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= Main |étape= Merge |type= RBID |clé= pubmed:17996473 |texte= Gaucher disease. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/RBID.i -Sk "pubmed:17996473" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd \ | NlmPubMed2Wicri -a ParkinsonFranceV1
This area was generated with Dilib version V0.6.29. |